Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene

Abstract

The present invention relates to antisense oligonucleotides that modulate the expression of and / or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Tumor Suppressor genes.

Description

CROSS REFERENCE[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 119,973, filed Dec. 4, 2008, U.S. Provisional Application No. 61 / 157,249, filed Mar. 4, 2009, U.S. Provisional Application No. 61 / 166,381, filed Apr. 3, 2009, and U.S. Provisional Application No. 61 / 154,594, filed Feb. 23, 2009, which applications are incorporated herein by reference in their entirety.FIELD OF THE INVENTION[0002]Embodiments of the invention comprise oligonucleotides modulating expression and / or function of Tumor Suppressor genes and associated molecules.BACKGROUND[0003]DNA-RNA and RNA-RNA hybridization are important to many aspects of nucleic acid function including DNA replication, transcription, and translation. Hybridization is also central to a variety of technologies that either detect a particular nucleic acid or alter its expression. Antisense nucleotides, for example, disrupt gene expression by hybridizing to target RNA, thereby interfering with RNA splicing, tran...

AI Technical Summary

Benefits of technology

[0008]Another embodiment provides a method of modulating function and / or expression of an Tumor Suppressor gene polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of the an antisense of the Tumor Suppressor gene polynucleotide; thereby modulating function and / or expression of the Tumor Suppressor gene polynucleotide in patient cells or tissues in vivo or in vitro.

[0009]Another embodiment provides a method of modulating function and / or expression of an Tumor Suppressor gene polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to an Tumor Suppressor gene antisense polynucleotide; thereby modulating function and / or expression of the Tumor Suppressor gene polynucleotide in patient cells or tissues in vivo or in vitro.

[0050]An embodiment of the invention provides a method of preventing or treating a disease associated with at least one Tumor Suppressor gene polynucleotide and / or at least one encoded product thereof, comprising administering to a patient a therapeutically effective dose of at least one antisense oligonucleotide that binds to a natural antisense sequence of said at least one Tumor Suppressor gene polynucleotide and modulates expression of said at least one Tumor Suppressor gene polynucleotide; thereby preventing or treating the disease associated with the at least one Tumor Suppressor gene polynucleotide and / or at least one encoded product thereof.

Problems solved by technology

Antisense nucleotides, for example, disrupt gene expression by hybridizing to target RNA, thereby interfering with RNA splicing, transcription, translation, and replication.

Images